“New CRBN Ligands Selectively Degrade BRD4, Potentially Reducing Off-Target Effects of IMiD-Based PROTAC Degraders”

https://pubmed.ncbi.nlm.nih.gov/38116854

Researchers have developed a new class of CRBN ligands that selectively degrade BRD4, potentially reducing off-target effects associated with traditional IMiD-based PROTAC degraders.